Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

Invitation to the Annual General Meeting of Multitude AG

View original at globenewswire.com
“Net result for the period EUR670,694”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Board of Directors proposes approval of the Combined Management Report, the Separate Financial Statements and the Consolidated Financial Statements 2025

    60% confidence

  • Martin Rechtsanwälte GmbH confirmed to the Board of Directors that it possesses the independence required to perform the independent proxy mandate

    60% confidence

  • The company is not aware of any facts that would preclude full discharge of the Board of Directors for the 2025 business year

    60% confidence

  • PricewaterhouseCoopers AG confirmed the Combined Management Report, Separate Financial Statements and Consolidated Financial Statements for 2025 without reservations

    60% confidence

  • The Board of Directors believes that the members standing for re-election collectively ensure that the Board has the competencies required for Multitude's targets, geographical presence and corporate culture

    60% confidence

  • The Board of Directors proposes an ordinary dividend distribution of EUR 0.55 per share, totaling EUR 11,776,677

    60% confidence

  • PricewaterhouseCoopers AG confirmed to the Board of Directors that it possesses the independence required to perform the auditor mandate

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com